Lang E, Lang PA, Shumilina E, Qadri SM, Kucherenko Y, Kempe DS, et al
Only 40% percent of patients with early stage HCC are eligible for potentially curative treatments (surgical resection, transplantation, local ablation), which prolong median survival times over 60 months ( c-Met Inhibitors So far, there are six Met inhibitors developed and they have been tested in 10 HCC clinical trials ( in vitro and in vivo trials ( Also, several clinical trials are (Table 1), including cabozanitinib, foretinib, cobazitinib, gefitinib, crizotinib, MSC2156119, AZD4547, MK2461, and INC280 ( TABLE 1 Drugs targeting HGF/c-Met in hepatocellular carcinoma patients
6,500 Current price is: 6,500
The copper complex is essential to GHK-Cus gene modulation activity without copper, the peptide has a narrower range of effects